**Baseline clinical characteristics and complement biomarkers of patients with C3G enrolled in two Phase II studies investigating the factor D inhibitor danicopan**

Steven D. Podosa, Howard Trachtmanb\*, Gerald Appelc, Andrew S. Bombackc, Bradley P. Dixond, Jack Wetzelse, H. Terence Cookf, Samir V. Parikhg, Matthew C. Pickeringf, James Tumlinh\*\*, Craig Langmani, Liz Lightstonef, C. John Speratij, Erica Dainak, Koenraad Peter Boumanl, Kara Ricem, Jane A Thanassia, Mingjun Huanga, Carla Nestern and Giuseppe Remuzzik

# Supplementary figure

# Supplementary Figure 1. Patient disposition



aN = 35 patients with C3G or IC-MPGN based on local laboratory biopsy analysis and medical history enrolled in Studies 204 and 205 (see methods for study design); bn = 5 patients did not provide consent/excluded for a re-biopsy to confirm their C3G diagnosis by analysis at a central laboratory and were not included in the biomarker analysis (three were adolescents who were not subjected to rebiopsy based on protocol and two did not provide consent); cn = 29 patients with biopsy-confirmed C3G at baseline based on new biopsies taken at baseline and analyzed at a single central laboratory.